Inc.;Genexine;Green Cross Corporation;Genexine, Inc.
发明人:
YANG, Sang-In,WOO, Jung-Won,YANG, Se Hwan,SUNG, Young Chul,PARK, Doo Hong,KIM, Min Woo
申请号：
EP16735196
公开号：
EP3243525A4
申请日:
2016.01.08
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.
